Brief: Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program And Extends Cash Runway Into 2026

Tvardi Therapeutics

22/01/2024 12:27

Jan 22 (Reuters) - Cara Therapeutics Inc  CARA.O :
    * CARA THERAPEUTICS PRIORITIZES LATE-STAGE NOTALGIA
PARESTHETICA
PROGRAM AND EXTENDS CASH RUNWAY INTO 2026
    * CARA THERAPEUTICS INC - PLANNED WORKFORCE REDUCTION OF UP
TO 50%
    * CARA THERAPEUTICS INC - CARA ENDED 2023 WITH APPROXIMATELY
$101
MILLION IN CASH; RUNWAY EXTENDED INTO 2026
    * CARA THERAPEUTICS INC - PHASE 3 PROGRAM IN ADVANCED
CHRONIC
KIDNEY DISEASE (CKD) TO BE DISCONTINUED
    * CARA THERAPEUTICS INC - FOCUS ON PHASE 2/3 PROGRAM IN
NOTALGIA
PARESTHETICA (NP), A NEUROPATHIC DISORDER WITH SIGNIFICANT UNMET
NEED

Source text for Eikon:  ID:nGNX4St6WH 
Further company coverage:  CARA.O 

 ((Reuters.Briefs@thomsonreuters.com;))